РОЗРОБЛЕННЯ ЗАСОБУ ДЛЯ ПОКРАЩЕННЯ КОГНІТИВНИХ ФУНКЦІЙ ТА ЗНИЖЕННЯ РІВНЯ ГОМОЦИСТЕЇНУ
Authors:
- Світлана РоманюкСРСвітлана Романюк
- Тетяна ТихоненкоТТТетяна Тихоненко
- Андрій СіромолотАСАндрій Сіромолот
- Михайло ГузикМГМихайло Гузик
- Наталія ЛуговськаНЛНаталія Луговська
- Тамара КучмеровськаТКТамара Кучмеровська
- Денис КолибоДКДенис Колибо
- Сергій КомісаренкоСКСергій Комісаренко
- 14 February 2022
- journal article
- research article
- Published by National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications) in Science and innovation
- Vol. 18 (1) , 66-75
Abstract
Introduction. Hyperhomocysteinemia is a dangerous metabolic disorder that leads to a number of diseases. Problem Statement. Urgent task is to develop pharmaceutical product for lowering the homocysteine levels without causing side effects. Purpose. To develop the dietary supplement for reducing high homocysteine levels, which has a minimum content of components that may cause side effects; to test the supplement effect on the cognitive abilities of animals and to commercialize the product. Materials and Methods. The developed dietary supplement Alfacognitin contains vitamins B6, B9, B12, C, and choline. For modelling experimental hyperhomocysteinemia in rats, the animals are kept on a diet rich in L-methionine. Blood homocysteine concentrations are determined by the ion exchange liquid column chromatography method with the use of an automatic amino acid analyzer. The behavioral responses and cognitive abilities of the rats have been studied with the use of behavioral tests (open field test, fear conditioning test, and social int e raction test). The production of Alfacognitin dietary supplement has been launched with Nutrimed Ltd. (Kyiv). Results. Alfacognitin has been shown to reduce homocysteine levels, to improve cognitive abilities, social interaction and communication skills, and to compensate functional memory and learning disorders in animals with hyperhomocysteinemia. Specifications for the dietary supplement have been approved, a pilot technology for obtaining the capsule form of the drug has been developed, and an experimental batch has been manufactured. Conclusions. Alfacognitin may reduce the homocysteine levels. Therefore, it may be used to normalize the functional state of the cardiovascular and nervous systems in patients with hyperhomocysteinemia, as well as to improve the cognitive functions, in particular in patients after COVID-19.Keywords
This publication has 27 references indexed in Scilit:
- The role of methionine on metabolism, oxidative stress, and diseasesAmino Acids, 2017
- Vitamin B12 deficiencyNature Reviews Disease Primers, 2017
- Vitamin C, Aging and Alzheimer’s DiseaseNutrients, 2017
- Development of the method for microbiological purity testing of recombinant human interleukin-7-based productThe Ukrainian Biochemical Journal, 2017
- Comparative investigation of methionine and novel formulation Metovitan protective effects in Wistar rats with testicular and epididymal toxicity induced by anti-tuberculosis drugs co-administrationFood and Chemical Toxicology, 2017
- A simple practice guide for dose conversion between animals and humanJournal of Basic and Clinical Pharmacy, 2016
- The Metabolic Burden of Methyl Donor Deficiency with Focus on the Betaine Homocysteine Methyltransferase PathwayNutrients, 2013
- Betaine supplementation decreases plasma homocysteine in healthy adult participants: a meta-analysisJournal of Chiropractic Medicine, 2013
- Is the prevalence of MTHFR C677T polymorphism associated with ultraviolet radiation in Eurasia?Journal of Human Genetics, 2012
- Methionine diet-induced hyperhomocysteinemia accelerates cerebral aneurysm formation in ratsNeuroscience Letters, 2011